{"product_id":"srpt-five-forces","title":"(SRPT) Sarepta Therapeutics, Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Sarepta Therapeutics, Inc. Porter's Five Forces Analysis helps you assess industry competition, buyer and supplier power, substitutes, and the threat of new entrants. The page already shows a real preview of the actual report, so you can review the content before buying. Purchase the full version for the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized oligo inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. relies on highly specialized oligo inputs for its 3 FDA-approved PMO medicines, so the supplier pool is narrow and pricing power sits with a few qualified chemical makers.\u003c\/p\u003e\n\u003cp\u003eFor rare-disease drugs, lot-to-lot quality and regulatory consistency matter more than the lowest unit cost, which raises switching risk and supply disruption risk.\u003c\/p\u003e\n\u003cp\u003eThat makes supplier leverage high: even small delays or impurity issues can hit clinical supply and commercial output.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eViral vector bottlenecks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGene therapy depends on scarce plasmid, viral vector, and fill-finish capacity, so GMP suppliers hold the upper hand. In 2025, AAV and lentiviral slots stayed tight across the CDMO market, with many programs waiting months for manufacturing time. For Sarepta Therapeutics, Inc., any delay or batch failure can push back trials and raise costs fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMO reliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics relies on a small set of CDMOs for certain development and scale-up steps, so supplier power is high. That dependence is costly: a partner switch can trigger fresh validation, comparability testing, and FDA-facing tech-transfer work that can take months. For a company with 2025 revenue near $1.8 billion, any delay in manufacturing can hit supply, launches, and cash flow fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulated quality standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers with FDA cGMP and global GMP capability are scarce, so Sarepta Therapeutics, Inc. has less room to switch vendors without risking compliance or product quality. That lifts supplier power, because fewer qualified partners can make critical materials and release batches under strict standards.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA cGMP narrows the vendor pool.\u003c\/li\u003e\n\u003cli\u003eLower-cost swaps can raise quality risk.\u003c\/li\u003e\n\u003cli\u003eCompliant suppliers gain pricing leverage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn practice, regulated inputs and validated processes make supplier replacement slow and costly, so experienced partners hold more leverage than in ordinary industries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIP and platform know-how\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. relies on partners with proprietary assays, vector know-how, and manufacturing methods, especially in AAV gene therapy and RNA platforms. That IP is hard to copy fast in-house, so key technical suppliers can push for better terms than ordinary vendors. This raises input risk because a single specialized partner can affect timing, yield, and scale.\u003c\/p\u003e\n\u003cp\u003eIn FY2025, that dependence matters more because Sarepta still needs external expertise to support highly technical development and production work. If a collaborator controls a critical assay or process step, it can have more leverage on price, capacity, and exclusivity. In plain terms: scarce know-how gives suppliers more bargaining power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProprietary know-how is hard to replace.\u003c\/li\u003e\n\u003cli\u003eTechnical partners can demand better terms.\u003c\/li\u003e\n\u003cli\u003eProcess bottlenecks raise switching costs.\u003c\/li\u003e\n\u003cli\u003eSupplier power is above normal vendor levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Supplier Dependence Threatens Sarepta’s Output Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupplier power is high for Sarepta Therapeutics, Inc. because its PMO drugs and gene therapy programs depend on scarce FDA-cGMP oligo, plasmid, vector, and fill-finish capacity. Switching is slow and costly, with validation and comparability work often taking months. In FY2025, revenue was about $1.8 billion, so any supply slip can hit output fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e~$1.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier pool\u003c\/td\u003e\n\u003ctd\u003eNarrow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching cost\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Sarepta Therapeutics, Inc.’s competitive pressures, supplier and buyer power, substitutes, and entry risks shaping pricing and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA quick Porter's Five Forces snapshot for Sarepta Therapeutics, Inc. that cuts through market noise and reveals strategic pressure fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eGives a clear, credible source trail for Sarepta Therapeutics, Inc., helping decision-makers verify key claims fast and act with more confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited patient pool\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta serves a tiny Duchenne muscular dystrophy pool, with DMD affecting about 1 in 3,500 to 5,000 male births and only subsets eligible for exon-skipping therapies such as exon 51, 45, or 53. That keeps buyer concentration low, but patients and caregivers still have real choice, so demand hinges on visible functional benefit and payer access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer reimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCommercial insurers and Medicaid programs can sharply limit Sarepta Therapeutics, Inc. access through prior authorization and narrow coverage rules, even for medically differentiated therapies. With Elevidys carrying a list price of about $3.2 million per treatment, reimbursement decisions can make or break demand. That gives payers outsized bargaining power over both volume and net price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist prescriber influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuromuscular specialists and major treatment centers shape Sarepta Therapeutics, Inc. therapy choice because they handle most Duchenne muscular dystrophy prescribing, not broad consumer demand. In 2025, Sarepta still relied on a concentrated prescriber base and $1.6 billion-plus annual net product sales, so specialist trust in efficacy, safety, and long-term data can swing uptake fast. That concentration can either lower or raise customer bargaining power, depending on how those prescribers view the data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHigh treatment switching friction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigh switching friction lowers customer bargaining power after adoption because Duchenne therapy is long-term and hard to replace; U.S. Duchenne affects about 1 in 3,500 to 5,000 male births. Still, payers and clinicians keep pressure on Sarepta Therapeutics, Inc. because continued use must prove benefit, safety, and tolerability. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow post-start switching power\u003c\/li\u003e\n\u003cli\u003eHigh scrutiny on outcomes\u003c\/li\u003e\n\u003cli\u003eRare-disease use favors persistence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAccess and affordability sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. sells rare-disease therapies where payers judge value, durability, and budget impact hard. For Duchenne muscular dystrophy, access still hinges on insurer approval and hospital formulary rules, so patients may want the drug but not control the sale. That lifts institutional buyer power above end-patient power, especially when annual specialty-drug costs can top six figures.\u003c\/p\u003e\n\u003cp\u003eIn 2025, that pressure stayed high as payers kept tightening prior authorization and reauthorization checks for gene and exon-skipping therapies. The result is simple: access risk is a pricing risk, and price cuts or outcomes data often matter more than patient loyalty.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReimbursement drives access.\u003c\/li\u003e\n\u003cli\u003eFormulary rules shape volume.\u003c\/li\u003e\n\u003cli\u003eBuyers can delay or deny use.\u003c\/li\u003e\n\u003cli\u003eHigh prices raise scrutiny fast.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer Power Shapes Sarepta’s $3.2M Duchenne Treatment Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyer power is high for Sarepta Therapeutics, Inc. because payers control access to $3.2 million Elevidys and other Duchenne therapies. Patients are rare and sticky after start, but prior authorization, reauthorization, and formulary rules let insurers and Medicaid shape volume and net price.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product sales\u003c\/td\u003e\n\u003ctd\u003e1.6B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElevidys list price\u003c\/td\u003e\n\u003ctd\u003e3.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDMD incidence\u003c\/td\u003e\n\u003ctd\u003e1 in 3,500-5,000 male births\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eSarepta Therapeutics, Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Sarepta Therapeutics, Inc. Porter's Five Forces Analysis you’ll receive after purchase—no placeholders, no edits needed. The full document is professionally written, fully formatted, and ready for immediate use. What you see here is the same file you’ll download instantly after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDuchenne competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. faces sharp Duchenne rivalry from exon-skipping and other mutation-targeted therapies, so even small differences in exon coverage can shift share. Because only about 8% to 13% of Duchenne patients may match a given exon-skipping approach, each product fights for a narrow pool, while broader gene-targeted drugs raise the bar. Buyers and payers will back the option that proves better durability, safety, and functional benefit in real-world use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGene therapy race\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics faces a tight DMD gene therapy race: Duchenne affects about 1 in 3,500 to 5,000 male births, so each trial and patient matters. Rival programs from Pfizer, Roche, and others can pull doctors, investors, and families toward competing next-gen genetic medicines. The fight is even harder because long-term benefit in DMD still has to be proven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical data competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical data rivalry is intense because head-to-head studies are rare, so Sarepta Therapeutics, Inc. competes on trial design, biomarker strength, and functional outcome data. In a niche market, even small efficacy or safety gaps can shift adoption fast, as seen when one dataset is more compelling than another. That makes every readout material, even with few direct rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta must keep its pipeline ahead of both its older exon-skipping drugs and rivals, because newer modalities can offer broader benefit and simpler dosing. That pressure is real: Elevidys is now the key growth engine, while the older Duchenne franchise must still defend share against next-gen gene and RNA programs. With 2025 revenue near $2 billion, continuous innovation is not optional.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNewer modalities can outclass older assets\u003c\/li\u003e\n\u003cli\u003eElevidys raises the bar inside the franchise\u003c\/li\u003e\n\u003cli\u003ePipeline breadth is needed to defend pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership and talent competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRare-disease gene therapy rivalry is not just about products; it is also a fight for scarce scientists, GMP manufacturing slots, and deal access. For Sarepta Therapeutics, Inc., that matters because know-how in AAV design, CMC scale-up, and regulatory execution can be a bigger edge than price.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTalent scarcity raises switching costs.\u003c\/li\u003e\n\u003cli\u003eManufacturing limits slow pipeline speed.\u003c\/li\u003e\n\u003cli\u003ePartners want proven execution first.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis makes rivalry broader than product launch battles: firms compete on platform quality, partner trust, and delivery speed. In gene therapy, one missed batch or trial delay can shift partnering leverage fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta Faces Fierce DMD Rivalry as Elevidys Drives Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high for Sarepta Therapeutics, Inc. because Duchenne drugs split a tiny eligible pool, so even small data wins can move share. Elevidys lifted 2025 revenue to about $2 billion, but Pfizer, Roche, and RNA rivals keep pressure on durability, safety, and label breadth. In gene therapy, execution can matter as much as price.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue\u003c\/td\u003e\n\u003ctd\u003e~$2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDuchenne match rate\u003c\/td\u003e\n\u003ctd\u003e8%-13%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDMD birth incidence\u003c\/td\u003e\n\u003ctd\u003e1 in 3,500-5,000 male births\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard of care support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupportive care is still the baseline alternative for many Duchenne muscular dystrophy patients. Physical therapy, corticosteroids, cardiac drugs, and respiratory support can slow decline and delay high-cost disease-modifying use, even if they do not replace it. With about 20,000 U.S. DMD cases and lifetime care costs often exceeding $1 million per patient, these lower-cost options keep substitute pressure meaningful for Sarepta Therapeutics, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOther mutation-specific drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients can switch to another exon-skipping drug if their DMD mutation fits that label, so substitutes are real but only inside each mutation bucket. Sarepta Therapeutics, Inc. faces this in a market with multiple FDA-approved exon-skipping options, which splits demand and weakens pricing power. That said, each drug still serves a narrow eligible pool, so substitution is partial, not full.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-gen genetic therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNext-gen genetic therapies, especially gene editing and micro-dystrophin, are the main long-term substitute risk for Sarepta Therapeutics, Inc. Duchenne muscular dystrophy affects about 1 in 3,500 to 5,000 boys, and one-time therapies could win share if they prove more durable than RNA drugs. If they also broaden eligibility, they could pressure Sarepta's exon-skipping base and its multi-product revenue stream.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEmerging multi-exon approaches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEmerging multi-exon therapies can substitute for Sarepta Therapeutics, Inc.'s single-exon products because they may cover more patients than exon-51, exon-45, or exon-53 drugs, which together address only a slice of Duchenne muscular dystrophy. In DMD, mutation-specific exon skipping leaves many patients outside each label, so broader-label medicines are attractive to clinicians because they cut testing and treatment-selection friction. That makes broader-platform competitors especially relevant as the DMD market stays fragmented by mutation class.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle-exon labels cover limited mutation groups.\u003c\/li\u003e\n\u003cli\u003eBroader platforms simplify prescribing decisions.\u003c\/li\u003e\n\u003cli\u003eMulti-exon rivals can widen addressable patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor Sarepta Therapeutics, Inc., the substitute risk rises if a competitor shows better efficacy across multiple mutation classes, because one regimen can replace several narrow products. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-drug management choices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-drug management stays a real substitute because families can choose steroids, physical therapy, cardiac care, and ventilatory support instead of advanced therapy. Duchenne muscular dystrophy affects about 1 in 3,500 to 5,000 male births, so even a small share of hesitant families can trim conversion rates. Safety worries, uncertain benefit, and high cost make watchful waiting a practical fallback.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eSupportive care can replace advanced therapy.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eHesitation lowers conversion, even with access.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eCost and safety are the main blockers.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta Faces Moderate Substitute Pressure as Alternatives Evolve\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes for Sarepta Therapeutics, Inc. is moderate: supportive care, steroids, and respiratory\/cardiac support can delay or replace advanced treatment for some families. Exon-skipping rivals also split demand by mutation, while gene editing and micro-dystrophin could be stronger long-run substitutes if they prove durable. With about 20,000 U.S. DMD cases, even small shifts matter.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003ePressure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupportive care\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOther exon-skipping drugs\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGene editing \/ micro-dystrophin\u003c\/td\u003e\n\u003ctd\u003eRising\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh regulatory barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh regulatory barriers keep new entrants out of Sarepta Therapeutics, Inc.’s gene-therapy niche. FDA approval can require rare-disease trials with only tens to low hundreds of patients, plus long-term follow-up for up to 15 years for some genetic medicines. That means heavy capital, deep regulatory know-how, and post-marketing duties, and the bar is even higher for first-in-class therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGene therapy and RNA drug development need heavy upfront capital for R\u0026amp;D, clinical trials, and GMP manufacturing, so the entry bar is high. Sarepta Therapeutics, Inc. operates in a field where one late-stage program can run for years and cost hundreds of millions of dollars, before any sales start. That long cash burn filters out smaller rivals and makes new entry far less likely.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNew entrants face a high bar because Sarepta Therapeutics, Inc. products need GMP-grade oligonucleotide or viral-vector production, plus tightly validated release testing. That kind of buildout is slow and costly; for example, Sarepta reported $1.9 billion in 2024 net product revenue, showing the scale already supporting its regulated supply chain. The result is a strong moat, since process validation and cold-chain quality control are hard to copy fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIP protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. faces a dense patent and licensing wall, so new entrants can’t copy its gene-therapy playbook fast. In this space, blocking patents and litigation risk make entry slow and costly, which keeps the threat of new entrants low.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDense IP slows launch timing\u003c\/li\u003e\n\u003cli\u003eLicenses raise entry costs\u003c\/li\u003e\n\u003cli\u003ePatent suits add legal risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScientific specialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eScientific specialization raises entry barriers for Sarepta Therapeutics, Inc. because DMD is a rare disease, affecting about 1 in 3,500 to 5,000 male births, so new entrants need deep biology, biomarker, and trial-design skills to compete. \u003c\/p\u003e\n\u003cp\u003eWithout Sarepta Therapeutics, Inc.'s investigator and patient networks, recruiting small cohorts is slow and costly, and even partnerships do not erase the learning curve. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare-patient access is the key bottleneck.\u003c\/li\u003e\n\u003cli\u003eDeep science knowledge is hard to copy.\u003c\/li\u003e\n\u003cli\u003ePartnerships help, but not enough.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWhy Sarepta’s Entry Barriers Keep New Competitors Out\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants is low for Sarepta Therapeutics, Inc. because FDA rules, 15-year follow-up for some genetic medicines, GMP manufacturing, and patent fences all raise cost and time. DMD is rare, about 1 in 3,500 to 5,000 male births, so entrants also face thin patient pools and slow trial access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA and long follow-up\u003c\/td\u003e\n\u003ctd\u003eSlow, costly entry\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP buildout\u003c\/td\u003e\n\u003ctd\u003eHeavy capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare-patient access\u003c\/td\u003e\n\u003ctd\u003eHard recruitment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234923585801,"sku":"srpt-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/srpt-five-forces.webp?v=1785732475","url":"https:\/\/dcfanalyst.com\/products\/srpt-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}